SEC Filings

Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT^® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

Filing date	Form	Description	View
Dec 22, 2020	4	Statement of changes in beneficial ownership of securities	View HTML 0001179110-20-012178.pdf 0001179110-20-012178.rtf 0001179110-20-012178.xls
Dec 18, 2020	4	Statement of changes in beneficial ownership of securities	View HTML 0001179110-20-012096.pdf 0001179110-20-012096.rtf 0001179110-20-012096.xls
Dec 17, 2020	8-K	Report of unscheduled material events or corporate event	View HTML 0001558370-20-014447.pdf 0001558370-20-014447.rtf 0001558370-20-014447.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
Dec 16, 2020	4	Statement of changes in beneficial ownership of securities	View HTML 0001179110-20-011989.pdf 0001179110-20-011989.rtf 0001179110-20-011989.xls
Dec 16, 2020	4	Statement of changes in beneficial ownership of securities	View HTML 0001179110-20-011988.pdf 0001179110-20-011988.rtf 0001179110-20-011988.xls
Dec 16, 2020	4	Statement of changes in beneficial ownership of securities	View HTML 0001179110-20-011990.pdf 0001179110-20-011990.rtf 0001179110-20-011990.xls
Dec 15, 2020	4	Statement of changes in beneficial ownership of securities	View HTML 0001179110-20-011906.pdf 0001179110-20-011906.rtf 0001179110-20-011906.xls
Dec 03, 2020	4	Statement of changes in beneficial ownership of securities	View HTML 0001179110-20-011608.pdf 0001179110-20-011608.rtf 0001179110-20-011608.xls
Dec 03, 2020	4	Statement of changes in beneficial ownership of securities	View HTML 0001179110-20-011606.pdf 0001179110-20-011606.rtf 0001179110-20-011606.xls
Dec 02, 2020	UPLOAD	UPLOAD	View HTML 0000000000-20-011535.pdf 0000000000-20-011535.rtf

Investors & Media

Transformative science, targeted medicines

SEC Filings

Pagination